OBJECTIVE: Charcot-Marie-Tooth disease (CMT) affects 1 in 2,500 people and is caused by mutations in more than 30 genes. Identifying the genetic cause of CMT is often necessary for family planning, natural history studies, and for entry into clinical trials. However genetic testing can be both expensive and confusing to patients and physicians. METHODS: We analyzed data from 1,024 of our patients to determine the percentage and features of each CMT subtype within this clinic population. We identified distinguishing clinical and physiological features of the subtypes that could be used to direct genetic testing for patients with CMT. RESULTS: Of 1,024 patients evaluated, 787 received CMT diagnoses. A total of 527 patients with CMT (67%) received a genetic subtype, while 260 did not have a mutation identified. The most common CMT subtypes were CMT1A, CMT1X, hereditary neuropathy with liability to pressure palsies (HNPP), CMT1B, and CMT2A. All other subtypes accounted for less than 1% each. Eleven patients had >1 genetically identified subtype of CMT. Patients with genetically identified CMT were separable into specific groups based on age of onset and the degree of slowing of motor nerve conduction velocities. INTERPRETATION: Combining features of the phenotypic and physiology groups allowed us to identify patients who were highly likely to have specific subtypes of CMT. Based on these results, we propose a strategy of focused genetic testing for CMT, illustrated in a series of flow diagrams created as testing guides.
OBJECTIVE:Charcot-Marie-Tooth disease (CMT) affects 1 in 2,500 people and is caused by mutations in more than 30 genes. Identifying the genetic cause of CMT is often necessary for family planning, natural history studies, and for entry into clinical trials. However genetic testing can be both expensive and confusing to patients and physicians. METHODS: We analyzed data from 1,024 of our patients to determine the percentage and features of each CMT subtype within this clinic population. We identified distinguishing clinical and physiological features of the subtypes that could be used to direct genetic testing for patients with CMT. RESULTS: Of 1,024 patients evaluated, 787 received CMT diagnoses. A total of 527 patients with CMT (67%) received a genetic subtype, while 260 did not have a mutation identified. The most common CMT subtypes were CMT1A, CMT1X, hereditary neuropathy with liability to pressure palsies (HNPP), CMT1B, and CMT2A. All other subtypes accounted for less than 1% each. Eleven patients had >1 genetically identified subtype of CMT. Patients with genetically identified CMT were separable into specific groups based on age of onset and the degree of slowing of motor nerve conduction velocities. INTERPRETATION: Combining features of the phenotypic and physiology groups allowed us to identify patients who were highly likely to have specific subtypes of CMT. Based on these results, we propose a strategy of focused genetic testing for CMT, illustrated in a series of flow diagrams created as testing guides.
Authors: Stephan Züchner; Irina V Mersiyanova; Maria Muglia; Nisrine Bissar-Tadmouri; Julie Rochelle; Elena L Dadali; Mario Zappia; Eva Nelis; Alessandra Patitucci; Jan Senderek; Yesim Parman; Oleg Evgrafov; Peter De Jonghe; Yuji Takahashi; Shoij Tsuji; Margaret A Pericak-Vance; Aldo Quattrone; Esra Battaloglu; Alexander V Polyakov; Vincent Timmerman; J Michael Schröder; Jeffery M Vance; Esra Battologlu Journal: Nat Genet Date: 2004-04-04 Impact factor: 38.330
Authors: K M Krajewski; R A Lewis; D R Fuerst; C Turansky; S R Hinderer; J Garbern; J Kamholz; M E Shy Journal: Brain Date: 2000-07 Impact factor: 13.501
Authors: J D England; G S Gronseth; G Franklin; G T Carter; L J Kinsella; J A Cohen; A K Asbury; K Szigeti; J R Lupski; N Latov; R A Lewis; P A Low; M A Fisher; D N Herrmann; J F Howard; G Lauria; R G Miller; M Polydefkis; A J Sumner Journal: Neurology Date: 2008-12-03 Impact factor: 9.910
Authors: Michael E Shy; Agnes Jáni; Karen Krajewski; Marina Grandis; Richard A Lewis; Jun Li; Rosemary R Shy; Janne Balsamo; Jack Lilien; James Y Garbern; John Kamholz Journal: Brain Date: 2004-01-07 Impact factor: 13.501
Authors: Dana Gabrikova; Martin Mistrik; Jarmila Bernasovska; Alexandra Bozikova; Regina Behulova; Iveta Tothova; Sona Macekova Journal: J Appl Genet Date: 2013-08-31 Impact factor: 3.240
Authors: José Berciano; Antonio García; Kristien Peeters; Elena Gallardo; Els De Vriendt; Ana L Pelayo-Negro; Jon Infante; Albena Jordanova Journal: J Neurol Date: 2015-04-01 Impact factor: 4.849
Authors: Mônica de Carvalho Alcântara; Marcello H Nogueira-Barbosa; Regina Maria França Fernandes; Geruza Alves da Silva; Charles Marques Lourenço; Heide H Sander; Wilson Marques Junior Journal: J Neurol Date: 2015-03-13 Impact factor: 4.849
Authors: Agnes Patzkó; Yunhong Bai; Mario A Saporta; István Katona; Xingyao Wu; Domenica Vizzuso; M Laura Feltri; Suola Wang; Lisa M Dillon; John Kamholz; Daniel Kirschner; Fazlul H Sarkar; Lawrence Wrabetz; Michael E Shy Journal: Brain Date: 2012-12 Impact factor: 13.501
Authors: Mari Auranen; Emil Ylikallio; Jussi Toppila; Mirja Somer; Sari Kiuru-Enari; Henna Tyynismaa Journal: Neurogenetics Date: 2013-03-03 Impact factor: 2.660